XOMA Royalty Corporation (NasdaqGM: XOMA)
Health Care · Biotechnology · US
$—
— today · — 1Y
XOMA Royalty Corporation (NasdaqGM: XOMA) operates in the Biotechnology industry within the Health Care sector.
trading between 22.29 and 45.22.
Tweenvest scores XOMA Royalty Corporation across four factors: quality 43/100, value 41/100, growth 100/100. Its strongest factor is growth.
XOMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $48.55M
- P/E
- —
- EPS
- 1.58
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $45.22
- 52-week low
- $22.29
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 14
- Next earnings
- —
About XOMA Royalty Corporation
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
- ISIN
- US98419J2069
- Founded
- 1981
- Listed since
- Jun 6, 1986
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.